For patients with metastatic NSCLC without driver mutation of EGFR, ALK, and ROS1, drugs that act on the PD-1/PDL-1 axis are predominantly used in the first-line setting with or without platinum chemotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.